Harmony Biosciences Holdings, Inc.
Financials
Valuation Metrics
Harmony Biosciences Holdings, Inc.'s Market Cap is $2.06B. At end of 2025 it was $2.16B. Ranked #2026 of 3,111 in US market (top 65%), #768 of 1,445 on NASDAQ (top 53%), #131 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.06B | US#2,026/3,111 Sec#131/269 |
| Revenue | $899M | US#1,999/3,111 Sec#57/269 |
| Net Income | $146M | US#1,427/3,111 Sec#51/269 |
| Total Assets | $1.27B | US#2,339/3,111 Sec#84/269 |
| Net Assets | $910M | US#1,849/3,111 Sec#71/269 |
| Employees | 293 | US#1,405/3,111 Sec#53/269 |
| Value | ||
| P/E | 14.15x | US#602/3,111 Sec#23/269 |
| P/B | 2.26x | US#1,342/3,111 Sec#63/269 |
| P/S | 2.29x | US#1,409/3,111 Sec#37/269 |
| EV/EBITDA | 7.19x | US#356/3,111 Sec#13/269 |
| FCF Yield | 16.58% | US#188/3,111 Sec#8/269 |
| Profitability | ||
| ROE | 16.00% | US#796/3,111 Sec#43/269 |
| ROA | 11.45% | US#349/3,111 Sec#32/269 |
| Op. Margin | 21.08% | US#852/3,111 Sec#42/269 |
| Revenue Growth | 16.59% | US#900/3,111 Sec#81/269 |
| Earnings Growth | -28.69% | US#1,738/3,111 Sec#53/269 |
| Financial Health | ||
| Debt Ratio | 39.71% | US#454/3,111 Sec#129/269 |
| Total Debt | $207M | US#2,204/3,111 Sec#92/269 |
| FCF | $342M | US#1,054/3,111 Sec#34/269 |
| Cash | $589M | US#973/3,111 Sec#49/269 |
| Current Ratio | 3.58x | US#641/3,111 Sec#178/269 |
| Net Debt/EBITDA | -1.64x | US#211/3,111 Sec#14/269 |
| Performance | ||
| 1Y Return | 3.49% | US#2,025/3,111 Sec#197/269 |
| 1M Return | -4.46% | US#1,808/3,111 Sec#121/269 |
| From 52W High | -12.89% | US#1,271/3,111 Sec#85/269 |
| 1Y MDD | -34.49% | US#1,665/3,111 Sec#109/269 |
| Trading | ||
| Volume | 836,718 shares | US#1,895/3,111 Sec#184/269 |
| Trading Value | $30M | US#1,903/3,111 Sec#142/269 |
| Per Share | ||
| EPS | $2.75 | US#1,040/3,111 Sec#32/269 |
| BPS | $15.10 | US#1,477/3,111 Sec#46/269 |
Company Info
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.